Cullinan Oncology (CGEM) EBITDA

Price: $7.8
Market Cap: $456.40M
Avg Volume: 453.26K
Country: US
Industry: Biotechnology
Sector: Healthcare
Beta: -0.052
52W Range: $6.85-30.189
Website: Cullinan Oncology

What is Cullinan Oncology's EBITDA?

  • Cullinan Oncology's annual EBITDA is $-190.34M.
  • Cullinan Oncology's quarterly EBITDA is $-54.97M.

What is EBITDA?

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a measure of a company's overall financial performance and is used as an alternative to net income in some circumstances.

How is EBITDA calculated?

EBITDA is calculated using the following formula:

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Related Metrics

Other important metrics to assess Cullinan Oncology's financial health include:

  • EBITDA Ratio - measures the company's EBITDA as a percentage of its revenue:
    • Annual: -
    • Quarterly: -
  • Growth EBITDA - measures the annual growth rate of the company's EBITDA:
    • Annual: -225.71%
    • Quarterly: -12.69%
  • Growth EBITDA Ratio - measures the annual growth rate of the company's EBITDA ratio:
    • Annual: 0.00%
    • Quarterly: 0.00%

These metrics provide insights into Cullinan Oncology's financial health and its ability to meet short-term obligations. Comparing these ratios with industry benchmarks can offer a deeper understanding of the company's performance.

Annual EBITDA

$-190.34M

Quarterly EBITDA

$-54.97M

Cullinan Oncology Historical EBITDA
Historical EBITDA Ratio (Annual)
Historical EBITDA Ratio (Quarterly)

Cullinan Oncology Historical EBITDA Metrics

The table below shows various financial metrics for each year, with the latest data available for the last fiscal year 2023.

Year EBITDA Growth EBITDA EBITDA Ratio Growth EBITDA Ratio
2023 $-190.34M -225.71% - 0.00%
2022 $151.41M 322.98% - 0.00%
2021 $-67.90M -12.66% -358.45% 0.00%
2020 $-60.27M -171.50% - 0.00%
2019 $-22.20M -52.65% - 0.00%
2018 $-14.54M 0.00% - 0.00%

Related Metrics

Explore detailed financial metrics and analysis for CGEM.